论文部分内容阅读
T-3262是富山化学工业综合研究所开发的新吡啶酮酸类抗菌剂,具广谱抗菌活性,对尿路感染的主要病因菌大肠杆菌、克雷白氏菌、沙雷氏菌、绿脓杆菌、粪肠球菌等的活性相同或优于已有喹诺酮类抗菌剂,尤其对革兰氏阳性菌,本品具有更强的活性。口服本品后以肾排泄为主,8小时尿中回收率为30～40%。在日本全国的临床研究中,本品对446例复杂尿路感染的总有效率为75.1%,对664株细菌的细菌学有效率为84%。本文为客观评价T-3262对复杂尿路感染的有效性,以氟哌酸为对照药物,对1987年8至12月在日本56所医疗单位对300例复
T-3262 is a new pyridone acid antibacterial agent developed by Toyama Chemical Industry Research Institute. It has broad-spectrum antibacterial activity against Escherichia coli, Klebsiella, Serratia, Pus Bacillus, Enterococcus faecalis and other activities of the same or better than the existing quinolone antibacterial agents, especially against Gram-positive bacteria, the product has a stronger activity. After oral administration of this product mainly to renal excretion, 8 hours urine recovery was 30 to 40%. In Japan’s national clinical studies, the product of 446 cases of complicated urinary tract infection in the total effective rate was 75.1%, 664 bacteria bacteriological efficiency was 84%. This article is an objective evaluation of T-3262 on the effectiveness of complex urinary tract infection with norfloxacin as a control drug, from August to December 1987 in Japan 56 medical units of 300 cases of complex